← Patent-cliff monitor small molecule ZORYVE ROFLUMILAST
Loss of exclusivity August 2037 latest FDA-listed patent expiry
Drug detail Brand name ZORYVE Active ingredient ROFLUMILAST Strength 0.3% Dosage form CREAM Route TOPICAL Modality Small molecule FDA approval July 2022 Marketing status RX
Listed patents Patent Expires Type 11129818 August 2037 use U-4578 9907788 June 2037 use U-4578 11819496 June 2037 use U-4578 12310956 June 2037 use U-4578 12005051 June 2037 use U-4578 11992480 June 2037 use U-4578 10940142 June 2037 product 12220409 June 2037 product 12016848 June 2037 product 12697329 June 2037 product 9884050 June 2037 product 12005052 June 2037 product 12042487 June 2037 product 12336983 June 2037 product 11793796 June 2037 product 12257242 June 2037 product 12011437 June 2037 product
Regulatory exclusivity Code Expires NPP June 2029 NPP October 2026
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.